Iressa is a medication that contains the active ingredient gefitinib. It is an oral tyrosine kinase inhibitor used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC). Here is a comprehensive description of Iressa (gefitinib) 250 mg tablets:

Mechanism of Action:

• Gefitinib is classified as a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). By inhibiting EGFR, gefitinib interferes with signaling pathways that promote cancer cell growth and survival.

Indications:

• Iressa (gefitinib) is primarily indicated for the treatment of:
  • Non-Small Cell Lung Cancer (NSCLC): Gefitinib is used as a first-line treatment in patients with advanced or metastatic NSCLC, particularly in those whose tumors have EGFR mutations.

Dosage:

• The standard dosage of Iressa is a 250 mg tablet taken orally once daily, with or without food. The specific dosage and duration of treatment are determined by a healthcare professional based on the patient’s condition and individual factors.

Administration:

• Iressa tablets should be swallowed whole with a glass of water. Crushing or breaking the tablets should be avoided.

Efficacy:

• Clinical studies have demonstrated the efficacy of gefitinib in extending progression-free survival and overall survival in patients with EGFR mutation-positive NSCLC.

Side Effects:

• Common side effects of gefitinib may include skin rash, diarrhea, nausea, fatigue, and changes in liver function. Some side effects can be more severe, and close monitoring is essential during treatment.

Precautions:

• Before starting Iressa, patients should inform their healthcare provider about their complete medical history, current medications, and any allergies. Regular monitoring of side effects and periodic imaging studies may be conducted during treatment.

Contraindications:

• Iressa is generally contraindicated in individuals with a known hypersensitivity to gefitinib or any of its components. It should be used with caution in patients with certain pre-existing medical conditions.

Storage:

• Iressa should be stored as per the manufacturer’s recommendations, ensuring proper temperature and handling to maintain its stability.

Compliance:

• Adherence to the prescribed dosage and administration schedule is crucial for achieving the best therapeutic outcomes with Iressa.

Iressa (gefitinib) provides targeted therapy for patients with specific EGFR mutations in NSCLC, offering a treatment option that addresses the underlying mechanisms of cancer growth. Its use should be carefully managed and monitored by qualified healthcare professionals to ensure optimal safety and efficacy for individual patients.